# OnCo record idea-crc-mss-immunotherapy-by-biomarker-not-by-line (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-crc-mss-immunotherapy-by-biomarker-not-by-line/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-crc-mss-immunotherapy-by-biomarker-not-by-line" ;
  schema:name "Select microsatellite stable patients for immunotherapy by a measured immune biomarker, not by how many treatments they have already failed"@en ;
  schema:description "Ninety-five percent of advanced bowel cancers ignore immunotherapy, and the only real signal so far came in patients without active liver secondaries. Trials keep enrolling by treatment line rather than by immune biology, which guarantees the responders are diluted away."@en ;
  schema:url <https://onco.cc/ideas/idea-crc-mss-immunotherapy-by-biomarker-not-by-line/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://europepmc.org/article/MED/38871975>, <https://europepmc.org/article/MED/26028255>, <https://clinicaltrials.gov/study/NCT05608044> ;
  onco:tag "colorectal-evidence" ;
  onco:related <https://onco.cc/roadmaps/colorectal-roadmap/>, <https://onco.cc/roadmaps/immunotherapy-roadmap/>, <https://onco.cc/ideas/idea-immunotherapy-mss-crc/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/pathways/tgf-beta/> ;
  onco:drugs <https://onco.cc/drugs/botensilimab/>, <https://onco.cc/drugs/balstilimab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/agenus/> ;
  onco:terms <https://onco.cc/terms/msi/>, <https://onco.cc/terms/cms-subtypes/>, <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/neoantigen/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-tme-immunosuppression/>, <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-trial-design/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024/>, <https://onco.cc/key-papers/paper-le-pd1-blockade-mismatch-repair-deficiency-nejm-2015/>, <https://onco.cc/key-papers/paper-galon-immune-contexture-colorectal-science-2006/>, <https://onco.cc/key-papers/paper-cms-guinney-nat-med-2015/> .